Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on September 19, 2017. The registrant is a foreign private issuer reporting pursuant to Rule 13A-16 or 15D-16 under the Securities Exchange Act of 1934. The filing incorporates a news release regarding an upcoming corporate event.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a vehicle to disseminate a news release rather than to report financial results.
Material Changes
No material changes to financial performance or operations are detailed in this filing. The document focuses on the announcement of a future event.
Guidance, Outlook, and Management Commentary
The primary content of this filing is the announcement that Aurinia Pharmaceuticals Inc. will host an R&D Day and Webcast on October 20, 2017, in New York, NY. This event is intended to provide updates on the company's research and development pipeline.
Key Facts for Investor Verification
- Verify the date and location of the R&D Day and Webcast (October 20, 2017, New York, NY).
- Confirm the company's status as a foreign private issuer filing under Form 40-F.
- Note that this filing incorporates by reference into the Registrant's Registration Statement on Form F-10 (File No. 333-206994).
- Check for subsequent filings for actual financial data, as none is included in this specific Form 6-K.